Analysis of the efficacy of specific immunotherapy with house-dust mite extracts in adults with allergic rhinitis and/or asthma;Analyse der effektivität der subkutanen immuntherapie mit hausstaubmilbenextrakten bei erwachsenen mit allergischer rhinitis und/oder asthma bronchiale

Laryngo- Rhino- Otologie

Volumn 82, Issue 4, 2003, Pages 272-280

  Polzehl, Doreen ^a   Keck, T ^a   Riechelmann, H ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Asthma; House dust mite; Provocation test; Rhinitis; Specific immunotherapy

Indexed keywords

ALLERGEN; ANTIHISTAMINIC AGENT; ANTIINFLAMMATORY AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; HOUSE DUST ALLERGEN; STEROID;

ALLERGIC RHINITIS; ALLERGY; ARTICLE; ASTHMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HOUSE DUST ALLERGY; HUMAN; IMMUNOTHERAPY; MULTICENTER STUDY; PRIORITY JOURNAL; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; RHINITIS; TREATMENT OUTCOME;

ADULT; ANTIGENS, DERMATOPHAGOIDES; ASTHMA; DESENSITIZATION, IMMUNOLOGIC; DOUBLE-BLIND METHOD; HUMANS; INJECTIONS, SUBCUTANEOUS; PYROGLYPHIDAE; RANDOMIZED CONTROLLED TRIALS; RHINITIS, ALLERGIC, PERENNIAL; TREATMENT OUTCOME;

EID: 0038274573     PISSN: 09358943     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-38935     Document Type: Article

References (75)

1. Verdiani P, Di Carlo S, Baronti A. Different prevalence and degree of nonspecific bronchial hyperreactivity between seasonal and perennial rhinitis. J Allergy Clin Immunol 1990; 86: 576-582
2. Leynaert B, Neukirch F, Demoly P, Bousquet J. Epidemiologic evidence for asthma and rhinitis comorbidity. J Allergy Clin Immunol 2000; 106: 201-205
3. Sears MR, Herbison GP, Holdaway MD, Hewitt CJ, Flannery EM, Silva PA. The relative risks of sensitivity to grass pollen, house dust mite and cat dander in the development of childhood asthma. Clin Exp Allergy 1989; 19: 419-424
4. Leynaert B, Bousquet J, Neukirch C, Liard R, Neukirch F. Perennial rhinitis: An independent risk factor for asthma in nonatopic subjects: results from the European Community Respiratory Health Survey. J Allergy Clin Immunol 1999; 104: 301-304
5. Abramson MJ, Puy RM, Weiner JM. Allergen immunotherapy for asthma. The Cochrane Library 4, 2001
6. Abramson MJ, Puy RM, Weiner JM. Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials. Am J Respir Crit Care Med 1995; 151: 969-974
7. Malling HJ. Immunotherapy as an effective tool in allergy treatment. Allergy 1998; 53: 461-472
8. Ross RN, Nelson HS, Finegold I. Effectiveness of specific immunotherapy in the treatment of asthma: a meta-analysis of prospective, randomized, double-blind, placebo-controlled studies. Clin Ther 2000; 22: 329-341
9. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998; 102: 558-562
10. Position paper: Immunotherapy (FAACI). The European Academy of Allergology and Clinical Immunology. Allergy 1993; 48: 7-35
11. Guyatt GH, Sackett DL, Cook DJ. Users' guides to the medical literature. II. How to use an article about therapy or prevention. A. Are the results of the study valid? Evidence-Base Medicine Working Group. JAMA 1993; 270: 2598-2601
12. Bucher HC, Guyatt GH, Cook DJ, Holbrook A, McAlister FA. Users' guides to the medical literature: XIX. Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate end points. Evidence-Based Medicine Working Group. JAMA 1999; 282: 771-778
13. Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn't. BMJ 1996; 312: 71-72
14. Egger M, Smith GD, Phillips AN. Meta-analysis: principles and procedures. BMJ 1997; 315: 1533-1537
15. Heges LV, Pigott TD. The power of statistical tests in meta-analysis. Psychol Methods 2001; 6: 203-217
16. Kelley GA, Tran ZV. Original metric vs. standardized effect sizes for meta-analysis of clinical data. Prev Cardiol 2001; 4: 40-45
17. Des Roches A, Paradis L, Knani J, Hejjaoui A, Dhivert H, Chanez P, Bousquet J. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. V. Duration of the efficacy of immunotherapy after its cessation. Allergy 1996; 51: 430-433
18. Kaldenbach T, Klimek L. Der Therapieerfolg eine Hyposensibilisierung mit Hausstaubmilbenextrakten ist größer bei Patienten mit positivem nasalem Provokationstest. Allergologie 2000; 23: 600
19. Bousquet J, Hejjaoui A, Clauzel AM, Guerin B, Dhivert H, Skassa-Brociek W, Michel FB. Specific immunotherapy with a standardized Dermatophagoides pteronyssinus extract. II. Prediction of efficacy of immunotherapy. J Allergy Clin Immunol 1988; 82: 971-977
20. Garcia-Ortega P, Merclo A. Marrugat J, Richart C. Decrease of skin and bronchial sensitization following short-intensive scheduled immunotherapy in mite-allergic asthma. Chest 1993; 103: 183-187
21. Haugaard L, Dahl R, Jacobsen L. A controlled dose-response study of immunotherapy with standardized, partially purified extract of house dust mite: clinical efficacy and side effects. J Allergy Clin Immunol 1993; 91: 709-722
22. Lofkvist T, Agrell B, Dreborg S, Svensson G. Effects of immunotherapy with a purified standardized allergen preparation of Dermatophagoides farinae in adults with perennial allergic rhinoconjunctivitis. Allergy 1994; 49:100-107
23. Mosbech H, Dreborg S, Frolund L, Ljungstedt-Pahlman I, Svendsen UG, Soborg M, Taudorf E, Weeke B. Hyposensitization in asthmatics with mPEG modified and unmodified house dust mite extract. II. Effect evaluated by challenges with allergen and histamine. Allergy 1989; 44: 499-509
24. Ohashi Y, Nakai Y, Tanaka A, Kakinoki Y, Washio Y, Yamada K, Sakamoto H, Nasako Y, Hayashi M. A comparative study of the clinical efficacy of immunotherapy and conventional pharmacological treatment for patients with perennial allergic rhinitis. Acta Otolaryngol Suppl 1998; 538: 102-112
25. Olaguibel JM, Tabar AI, Garcia BE, Martin S, Rico P. Long-term immunotherapy with an optimal maintenance dose of a standardized Dermatophagoides pteronyssinus extract in asthmatic patients. J Investig Allergol Clin Immunol 1999; 9: 110-116
26. Pecoud A, Nicod L, Badan M, Agrell B, Dreborg S, Kolly M. Effects of one-year hyposensitization in allergic rhinitis. Comparison of two house dust mite extracts. Allergy 1990; 45: 386-392
27. Pichler CE, Helbling A, Pichler WJ. Three years of specific immunotherapy with house-dust-mite extracts in patients with rhinitis and asthma: significant improvement of allergen-specific parameters and of nonspecific bronchial hyperreactivity. Allergy 2001; 56: 301-306
28. Rogala B, Gluck J. Allergen-specific IgE in circulating immune complexes in patients with inhalant allergy undergoing specific immunotherapy. J Investig Allergol Clin Immunol 1999; 9: 183-189
29. Baur X. (Hyposensitization in bronchial asthma - still a current therapeutic procedure?). Med Klin 1989; 84: 439-444
30. Maunsell K, Wraith DG, Hughes AM. Hyposensitisation in mite asthma. Lancet 1971; 1: 967-968
31. Buchanan DJ, Hillis A, Williams PN. A double blind controlled trial of Bencard house dust mite (Migen) hyposensitisation in Zambian asthmatics. Med J Zambia 1980; 15: 14-16
32. Marques RA, Avila R. Results of a clinical trial with a Dermatophagoides pteronyssinus tyrosine adsorbed vaccine. Allergol et Immunopathol 1978; 6: 231-235
33. Blainey AD, Phillips MJ, Ollier S, Davies RJ. Hyposensitization with a tyrosine adsorbed extract of Dermatophagoides pteronyssinus in adults with perennial rhinitis. A controlled clinical trial. Allergy 1984; 39: 521-528
34. D'Souza MF, Pepys J, Wells ID, Tai E, Palmer F, Overell BG, McGrath IT, Megson M. Hyposensitization with Dermatophagoides pteronyssinus in house dust allergy: a controlled study of clinical and immunological effects. Clin Allergy 1973; 3: 177-193
35. Gabriel MS, Ng HK, Allan WG, Hill LE, Nunn AJ. Study of prolonged hyposensitization with D. pteronyssinus extract in allergic rhinitis. Clin Allergy 1977; 7: 325-339
36. Machiels JJ, Lebrun PM, Jacquemin MG, Saint-Remy JM. Significant reduction of nonspecific bronchial reactivity in patients with Dermatophagoides pteronyssinus-sensitive allergic asthma under therapy with allergen-antibody complexes. Am Rev Respir Dis 1993; 147: 1407-1412
37. Machiels JJ, Somville MA, Lebrun PM, Lebecque SJ, Jacquemin MG, Saint-Remy JM. Allergic bronchial asthma due to Dermatophagoides pteronyssinus hypersensitivity can be efficiently treated by inoculation of allergen-antibody complexes. J Clin Invest 1990; 85: 1024-1035
38. Aas K. Hyposensitization in house dust allergy asthma. A double-blind controlled study with evaluation of the effect on bronchial sensitivity to house dust. Acta Paediatr Scand 1971; 60: 264-268
39. Van Bever HP, Stevens WJ. Effect of hyposensitization upon the immediate and late asthmatic reaction and upon histamine reactivity in patients allergic to house dust mite (Dermatophagoides pteronyssinus). Eur Respir J 1992; 5: 318-322
40. Van Bever HP, Stevens WJ. Evolution of the late asthmatic reaction during immunotherapy and after stopping immunotherapy. J Allergy Clin Immunol 1990; 86: 141-146
41. Cantani A, Areese G, Lucenti P, Gagliesi D, Bartolucci M. A three-year prospective study of specific immunotherapy to inhalant allergens: evidence of safety and efficacy in 300 children with allergic asthma. J Investig Allergol Clin Immunol 1997; 7: 90-97
42. Cools M, Van Bever HP, Weyler JJ, Stevens WJ. Long-term effects of specific immunotherapy, administered during childhood, in asthmatic patients allergic to either house-dust mite or to both house-dust mite and grass pollen. Allergy 2000; 55: 69-73
43. Des Roches A, Paradis L, Menardo JL, Bouges S, Daurse JP, Bousquet J. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol 1997; 99: 450-453
44. Gruber W, Eber E, Mileder P, Modl M, Weinhandl E, Zach MS. Effect of specific immunotherapy with house dust mite extract on the bronchial responsiveness of paediatric asthma patients. Clin Exp Allergy 1999; 29: 176-181
45. Malet A, Lluch M, Valero AL, Casanovas M. Clinical and immunological effects of immunotherapy with glutaraldehyde modified house dust mite extract. Allergol Immunopathol (Madr) 1994; 22: 226-232
46. Murray AB, Ferguson AC, Morrison BJ. Non-allergic bronchial hyperreactivity in asthmatic children decreases with age and increases with mite immunotherapy. Ann Allergy 1985; 54: 541-544
47. Peroni DG, Piacentini GL, Martinati LC, Warner JO, Boner AL. Double-blind trial of house-dust mite immunotherapy in asthmatic children resident at high altitude. Allergy 1995; 50: 925-930
48. Price JF, Warner JO, Hey EN, Turner MW, Soothill JF. A controlled trial of hyposensitization with adsorbed tyrosine Dermatophagoides pteronyssinus antigen in childhood asthma: in vivo aspects. Clin Allergy 1984; 14: 209-219
49. Wahn U, Schweter C, Lind P, Lowenstein H. Prospective study on immunologic changes induced by two different Dermatophagoides pteronyssinus extracts prepared from whole mite culture and mite bodies. J Allergy Clin Immunol 1988; 82: 360-370
50. Warner JO, Price JF, Soothill JF, Hey EN. Controlled trial of hyposensitisation to Dermatophagoides pteronyssinus in children with asthma. Lancet 1978; 2: 912-915
51. Baceciler NN, Isik U, Barlan IB, Basaran MM. Efficacy of sublingual immunotherapy in children with asthma and rhinitis: a double-blind, placebo-controlled study. Pediatr Pulmonol 2001; 32: 49-55
52. Mungan D, Misirligil Z, Gurbuz L. Comparison of the efficacy of subcutaneous and sublingual immunotherapy in mite-sensitive patients with rhinitis and asthma - a placebo controlled study. Ann Allergy Asthma Immunol 1999; 82: 485-490
53. Bousquet J, Scheinmann P, Guinnepain MT, Perrin-Fayolle M, Sauvaget J, Tonnel AB, Pauli G, Caillaud D, Dubost R, Leynadier F, Vervloet D, Herman D, Galvain S, Andre C. Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites: a double-blind, placebo-controlled study. Allergy 1999; 54: 249-260
54. Passalacqua G, Albano M, Fregonese L, Riccio A, Pronzato C, Mela GS, Canonica GW. Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis. Lancet 1998; 351: 629-632
55. Tari MG, Mancino M, Monti G. Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A double-blind study. Allergol Immunopathol (Madr) 1990; 18: 277-284
56. Guez S, Vatrinet C, Fadel R, Andre C. House-dust-mite sublingual-swallow immunotherapy (SLIT) in perennial rhinitis: a double-blind, placebo-controlled study. Allergy 2000; 55: 369-375
57. Hirsch T, Sahn M, Leupold W. Double-blind placebo-controlled study of sublingual immunotherapy with house dust mite extract (D. pt.) in children. Pediatr Allergy Immunol 1997; 8: 21-27
58. Pajno GB, Morabito L, Barberio G, Parmiani S. Clinical and immunologic effects of long-term sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, placebo-controlled study. Allergy 2000; 55: 842-849
59. Smith AP. Hyposensitization with Dermatophagoides pteronyssinus antigen: trial in asthma induced by house dust. Br Med J 1971; 4: 204-206
60. Mite Allergy Subcommittee of the Research Committee of the British Thoracic Association. A trial of house dust mite extract in bronchial asthma. Br J Dis Chest 1979; 73: 260-270
61. Gaddie J, Skinner C, Palmer KN. Hyposensitisation with house dust mite vaccine in bronchial asthma. Br Med J 1976; 2: 561-562
62. Corrado OJ, Pastorello E, Ollier S, Cresswell L, Zanussi C, Ortolani C, lucorvaia A, Fugazza A, Lovely JR, Harris RI et al. A double-blind study of hyposensitization with an alginate conjugated extract of D. pteronyssinus (Conjuvac) in patients with perennial rhinitis. I. Clinical aspects. Allergy 1989; 44: 108-115
63. Ewan PW, Alexander MM, Snape C, Ind PW, Agrell B, Dreborg S. Effective hyposensitization in allergic rhinitis using a potent partially purified extract of house dust mite. Clin Allergy 1988; 18: 501-508
64. Franco C, Barbadori S, Freshwater LL, Kordash TR. A double-blind, placebo controlled study of Alpare mite D. pteronyssinus immunotherapy in asthmatic patients. Allergol Immunopathol (Madr) 1995; 23: 58-66
65. McHugh SM, Lavelle B, Kemeny DM, Patel S, Ewan PW. A placebo-controlled trial of immunotherapy with two extracts of Dermatophagoides pteronyssinus in allergic rhinitis, comparing clinical outcome with changes in antigen-specific IgE, IgG, and IgG subclasses. J Allergy Clin Immunol 1990; 86: 521-531
66. Pichler CE, Marquardsen A, Sparholt S, Lowenstein H, Bircher A, Bischof M, Pichler WJ. Specific immunotherapy with Dermatophagoides pteronyssinus and D. farinae results in decreased bronchial hyperreactivity. Allergy 1997; 52: 274-283
67. Olsen OT, Larsen KR, Jacobsan L, Svendsen UG. A 1-year, placebo-controlled, double-blind house-dust-mite immunotherapy study in asthmatic adults. Allergy 1997; 52: 853-859
68. Bousquet J, Calvayrac P, Guerin B, Hejjaoui A, Dhivert H, Hewitt B, Michel FB. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. I. In vivo and in vitro parameters after a short course of treatment. J Allergy Clin Immunol 1985; 76: 734-744
69. Newton DA, Maberley DJ, Wilson R. House dust mite hyposensitization. Br J Dis Chest 1978; 72: 21-28
70. Grembiale RD, Camporota L, Naty S, Tranfa CM, Djukanovic R, Marsico SA. Effects of specific immunotherapy in allergic rhinitic individuals with bronchial hyperresponsiveness. Am J Respir Crit Care Med 2000; 162: 2048-2052
71. Roisman GL, Peiffer C, Lacronique JG, Le Cae A, Dusser DJ. Perception of bronchial obstruction in asthmatic patients. Relationship with bronchial eosinophilic inflammation and epithelial damage and effect of corticosteroid treatment. J Clin Invest 1995; 96: 12-21
72. Mosbech H, Dreborg S, Frolund L, Ljungstedt-Pahlman I, Svendsen UG, Soborg M, Taudorf E, Wecke B. Hyposensitization in asthmatics with mPEG modified and unmodified house dust mite extract. I. Clinical effect evaluated by diary cards and a retrospective assessment. Allergy 1989; 44: 487-498
73. Pauli G, Bessot JC, Bigot H, Delaume G, Hordle DA, Hirth C, Thierry R. Clinical and immunologic evaluation of tyrosine-adsorbed Dermatophagoides pteronyssinus extract: a double-blind placebo-controlled trial. J Allergy Clin Immunol 1984; 74: 524-535
74. Mellerup MT, Hahn GW, Poulsen LK, Malling H. Safety of allergen-specific immunotherapy. Relation between dosage regimen, allergen extract, disease and systemic side-effects during induction treatment. Clin Exp Allergy 2000; 30: 1423-1429
75. Tabar AI, Garcia BE, Rodriguez A, Olaguibel JM, Muro MD, Quiree S. A prospective safety-monitoring study of immunotherapy with biologically standardized extracts. Allergy 1993; 48: 450-453